SCYNEXIS, Inc. Announces First Patient Dosed in Phase 3 Open-label Study Evaluating Oral Ibrexafungerp in Candida auris Infections (CARES)

Oct 15, 2018

SCYNEXIS Supports AMR Challenge and Fungal Disease Awareness Week

Oct 1, 2018

SCYNEXIS to Present an Overview of the Company's Pipeline at IDWeek 2018

Sep 26, 2018

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

Sep 25, 2018

SCYNEXIS, Inc. Presents Ibrexafungerp Data at the 2018 ESCMID/ASM Conference on Drug Development

Sep 4, 2018

SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences

Aug 29, 2018

SCYNEXIS Reports Second Quarter 2018 Financial Results and Provides Company Update

Aug 9, 2018

The World Health Organization Recognizes New Antifungal Class by Granting "ibrexafungerp" to SCYNEXIS as the International Non-Proprietary Name for SCY-078

Jul 18, 2018

SCYNEXIS Reports Positive Results from Phase 2b Dose-Finding Study of Oral SCY-078 in Vulvovaginal Candidiasis

Jul 10, 2018

SCYNEXIS Announces the Presentation of SCY-078 Data at the Teratology Society 58th Annual Meeting

Jun 27, 2018